Citations

Clear

58 citation(s) found for "Wang, Eric W".

Outcomes of Immunotherapy Treatment in Sinonasal Mucosal Melanoma
Kshirsagar, Rijul S. , Harris, Jacob , Chang, Eugene H. , Fung, Nicholas , Hong, Michelle , Johnson, Brian J. , Kohanski, Michael A. , Lee, Jivianne T. , Nabavizadeh, Seyed Ali , Obermeyer, Isaac P. , Pandrangi, Vivek C. , Smith, Timothy L. , Wang, Marilene B. , Lazor, Jillian W. , Mitchell, Tara C. , Adappa, Nithin D. , Adappa, Nithin D. , Harris, Jacob , Lee, Jivianne T , Obermeyer, Isaac P , Smith, Timothy L , Snyderman, Carl H , Kuan, Edward C , Kshirsagar, Rijul S , Eide, Jacob G. , Abiri, Arash , Beswick, Daniel M. , Fung, Nicholas, Le, Christopher H. , Pinheiro‐Neto, Carlos , Suh, Jeffrey D. , Wang, Eric W , Choby, Garret , Geltzeiler, Mathew , Adappa, Nithin D.

Mayo Clinic

American Journal of Rhinology & Allergy | January 9, 2025 | Volume: 39 | Issue: 2 | Pages: 102-108

10.1177/19458924241308953 | PMID 39782303 Get It

Background Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma. Objective We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma. Methods A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded. Results 52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT ( n = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab ( n = 17, 32.7%) or pembrolizumab ( n = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively. Conclusion Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response.
Correlation of the Sinonasal Outcome Test‐22 With the University of Washington Quality of Life in Assessing Quality of Life in Sinonasal Malignancy Utilizing a Multicenter Prospective Observational Cohort Registry
Fleseriu, Cara M. , Beswick, Daniel M. , Maoz, Sabrina L. , Hwang, Peter H. , Adappa, Nithin D. , Getz, Anne E., Humphreys, Ian M. , Traylor, Katie , Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Patel, Zara M. , Smith, Timothy L. , Wang, Marilene B. , Wang, Eric W , Beswick, Daniel , Maoz, Sabrina L , Hwang, Peter H , Humphreys, Ian M , Jafari, Aria , Kingdom, Todd T , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Choby, Garret , Kuan, Edward C , Adappa, Nithin D. , Geltzeiler, Mathew , Abuzeid, Waleed M. , Pinheiro‐Neto, Carlos , Le, Christopher H. , Lee, Jivianne K., Nayak, Jayakar V. , John, Maie A. St. , Suh, Jeffrey D. , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | January 6, 2025 | Volume: 15 | Issue: 4 | Pages: 451-454

10.1002/alr.23522 | PMID 39761380 Get It

Pathologic dural invasion is associated with regional recurrence in olfactory neuroblastoma: A multi‐institutional study
Tang, Anthony , Fung, Nicholas , Champagne, Pierre‐Olivier , Fernandez‐Miranda, Juan C. , Gardner, Paul , Hwang, Peter H. , Nayak, Jayakar V. , Patel, Chirag , Patel, Zara M. , Celda, María Peris, Sanusi, Olabisi , Thorp, Brian D. , Zenonos, Georgios A. , Zwagerman, Nathan T. , Nayak, Jayakar V , Patel, Zara , Pinheiro-Neto, Carlos, Snyderman, Carl H , Wang, Eric W , Choby, Garret , Hwang, Peter H , Taori, Suchet , Fung, Nicholas, Almeida, João Paulo , Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van , Geltzeiler, Mathew , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | November 13, 2024 | Volume: 15 | Issue: 4 | Pages: 373-383

10.1002/alr.23489 | PMID 39535364 Get It

AbstractObjectiveNeck metastases are a poor prognostic factor in olfactory neuroblastoma (ONB). Pathologic dural invasion (pathDI) may increase the risk of neck metastases due to invasion of dural lymphatics. We aim to evaluate the prognostic value of pathDI in predicting rates of neck metastases and recurrence using a large, multicenter database of ONB patients.Data sourcesRetrospective review of a prospective, multicenter database of electronic health records of all patients who presented with ONB between 2005 and 2021 at nine tertiary academic care centers within North America.Review methodsClinicopathologic features including modified Kadish staging systems, margin status, treatment modalities, Hyams grading, follow‐up time, and survival.ResultsOf 258 ONB patients, 189 patients met the inclusion criteria. The 10‐year neck recurrence‐free survival (neck‐RFS) rates were 85.7% (75.6‒97.3) and 61.8% (47.9‒79.8) for patients without and with pathDI, respectively (p = 0.018). Time‐to‐event multivariable regression analysis found pathDI to have an odds ratios of 9.7 (95% confidence interval [CI] 1.2–80.4, p = 0.04) for neck‐RFS and 9.5 for RFS at any site (95% CI 1.1–83.3, p = 0.04).ConclusionIn multivariable analysis, the presence of pathDI appears to be the strongest predictor of neck recurrence and recurrence at any site. Future studies exploring the benefit of elective neck dissection or radiation for patients with pathDI may impact disease management.
Endoscopic‐assisted transorbital extended orbital exenteration: A multi‐institutional preclinical study
Roccuzzo, Giuseppe , Vyskocil, Erich , Kandathil, Sam Augustine , Peris‐Celda, Maria , Leong, Samuel , Herman, Philippe , Vérillaud, Benjamin , Bresson, Damien, Schreiber, Alberto , Arosio, Alberto Daniele , Valentini, Marco , Pozzi, Fabio , Volpi, Luca , Nicolai, Piero , Ferrari, Marco , Kandathil, Sam Augustine , Borsetto, Daniele , Taboni, Stefano , Mattavelli, Davide , Ferrari, Marco , Schreiber, Alberto , Hirtler, Lena , Agosti, Edoardo , Kuan, Edward C , Wang, Eric W , Sharma, Rishi , Vinciguerra, Alessandro , Bresson, Damien , Erović, Boban M. , Vural, Alperen , Dallan, Iacopo , Doglietto, Francesco , Mattavelli, Davide , Rampinelli, Vittorio , Battaglia, Paolo , Turri‐Zanoni, Mario , Bignami, Maurizio , Castelnuovo, Paolo

Mayo Clinic

Head & Neck | July 3, 2024 | Volume: 46 | Issue: 9 | Pages: 2327-2339

10.1002/hed.27858 | PMID 38958177 Get It

Abstract Background Sinonasal malignancies with orbital invasion have dismal prognosis even when treated with orbital exenteration (OE). Sugawara et al. developed a surgical strategy called “extended‐OE (EOE),” showing encouraging outcomes. We hypothesized that a similar resection is achievable under endoscopic guidance through the exenterated orbit (endoscopic‐EOE). Methods The study was conducted in three institutions: University of Vienna; Mayo Clinic; University of Insubria; 48 orbital dissections were performed. A questionnaire was developed to evaluate feasibility and safety of each step, scoring from 1 to 10, (“impossible” to “easy,” and “high risk” to “low risk,” respectively), most likely complication(s) were hypothesized. Results The step‐by‐step technique is thoroughly described. The questionnaire was answered by 25 anterior skull base surgeons from six countries. Mean, median, range, and interquartile range of both feasibility and safety scores are reported. Conclusions Endoscopic‐EOE is a challenging but feasible procedure. Clinical validation is required to assess real‐life outcomes.
University of Washington Quality of Life subdomain outcomes after treatment of sinonasal malignancy: A prospective, multicenter study
Maoz, Sabrina L. , Golzar, Autreen , Hwang, Peter H. , Adappa, Nithin D. , Getz, Anne E., Humphreys, Ian M. , Chan, Erik, Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Lazor, Jillian W. , Nabavizadeh, Ali , Adappa, Nithin D. , Patel, Zara M. , Smith, Timothy L. , Storm, Phillip B. , Wang, Marilene B. , Sim, Myung‐Shin , Choby, Garret , Hwang, Peter H , Wang, Eric W , Kuan, Edward C , Humphreys, Ian M , Jafari, Aria , Kingdom, Todd T , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Beswick, Daniel , Maoz, Sabrina L , Choby, Garret , Adappa, Nithin D. , Geltzeiler, Mathew , Le, Christopher H. , Pinheiro‐Neto, Carlos , Fischer, Jakob L. , Abuzeid, Waleed M. , Nayak, Jayakar V. , Resnick, Adam , John, Maie A. St. , Suh, Jeffrey D. , Beswick, Daniel M.

Mayo Clinic

International Forum of Allergy & Rhinology | June 17, 2024 | Volume: 14 | Issue: 10 | Pages: 1568-1581

10.1002/alr.23386 | PMID 38884276 Get It

AbstractPurposeSinonasal malignancies (SNMs) adversely impact patients’ quality of life (QOL) and are frequently identified at an advanced stage. Because these tumors are rare, there are few studies that examine the specific QOL areas that are impacted. This knowledge would help improve the care of these patients.MethodsIn this prospective, multi‐institutional study, 273 patients with SNMs who underwent definitive treatment with curative intent were evaluated. We used the University of Washington Quality of Life (UWQOL) instrument over 5 years from diagnosis to identify demographic, treatment, and disease‐related factors that influence each of the 12 UWQOL subdomains from baseline to 5 ‐years post‐treatment.ResultsMultivariate models found endoscopic resection predicted improved pain (vs. nonsurgical treatment CI 2.4, 19.4, p = 0.01) and appearance versus open (CI 27.0, 35.0, p < 0.001) or combined (CI 10.4, 17.1, p < 0.001). Pterygopalatine fossa involvement predicted worse swallow (CI −10.8, −2.4, p = 0.01) and pain (CI −17.0, −4.0, p < 0.001). Neck dissection predicted worse swallow (CI −14.8, −2.8, p < 0.001), taste (CI −31.7, −1.5, p = 0.02), and salivary symptoms (CI −28.4, −8.6, p < 0.001). Maxillary involvement predicted worse chewing (CI 9.8, 33.2; p < 0.001) and speech (CI −21.8, −5.4, p < 0.001) relative to other sites. Advanced T stage predicted worse anxiety (CI −13.0, −2.0, p = 0.03).ConclusionsSurgical approach, management of cervical disease, tumor extent, and site of involvement impacted variable UWQOL symptom areas. Endoscopic resection predicted better pain, appearance, and chewing compared with open. These results may aid in counseling patients regarding potential QOL expectations in their SNM treatment and recovery course.
Multi‐center study on sellar reconstruction after endoscopic transsphenoidal pituitary surgery
Ali, Hawa M. , Leland, Evelyn M. , Stickney, Emily, Lohse, Christine M. , Iyoha, Ehiremen, Valappil, Benita, Filimonov, Andrey , Goetschel, Kaitlin , Young, Sarah C. , Shahin, Maryam N. , Sanusi, Olabisi , Sonfack, Davaine Joel Ndongo , Champagne, Pierre‐Olivier , Zwagerman, Nathan T. , Gardner, Paul A. , Zenonos, Georgios A. , Link, Michael J. , Peris‐Celda, Maria , Stokken, Janalee K., Stokken, Janalee K. , Wang, Eric W , Snyderman, Carl H , Van Gompel, Jamie, Choby, Garret , Carlson, Matthew L , Nadeau, Sylvie , Geltzeiler, Mathew , Gompel, Jamie J. Van , Choby, Garret , Pinheiro‐Neto, Carlos

Mayo Clinic

International Forum of Allergy & Rhinology | June 17, 2024 | Volume: 14 | Issue: 10 | Pages: 1558-1567

10.1002/alr.23382 | PMID 38884280 Get It

AbstractIntroductionSurgical techniques for sellar reconstruction include no reconstruction, use of synthetic materials, autologous grafts, and/or vascularized flaps. The aim of this study was to conduct a multi‐center study comparing the efficacy and postoperative morbidity associated with different sellar reconstruction techniques.MethodsA retrospective chart review of patients who underwent endoscopic transsphenoidal surgery for pituitary tumors from five participating sites between January 2021 and March 2023 was performed. The variables included demographics, tumor characteristics, reconstruction technique, postoperative cerebrospinal fluid leak (CSF) leak, and 22‐item Sino‐Nasal Outcome Test (SNOT‐22) scores. Comparisons of postoperative complications, SNOT‐22 scores, and duration of surgery by type of onlay reconstruction were evaluated using Fisher's exact test, analysis of variance, and Kruskal‒Wallis test.ResultsFive hundred and one patients were identified. The median tumor size was 2.1 cm, and 64% were non‐functioning. Intraoperative CSF leak was identified in 38% of patients. A total of 89% of patients underwent onlay reconstruction: 49% were reconstructed with mucosal grafts, 35% with nasoseptal flaps, and 5% with other onlay techniques. Nasoseptal flaps were utilized more frequently in the setting of giant pituitary adenomas (>3 cm), medial cavernous sinus wall resection, and high‐flow intraoperative CSF leaks. Cases who utilized mucosal grafts had an overall shorter operating time (median: 183 min vs. 240 min; p < 0.001). Five postoperative CSF leaks were identified, and therefore, statistical analysis could not be performed for this complication.ConclusionThe effectiveness and morbidity of different sellar reconstruction techniques are comparable. Vascularized flaps were utilized more frequently in the setting of larger tumors and high‐flow intraoperative CSF leaks.
ICSNT Primer for the Skull Base Community: Navigating the Landscape of Sinonasal Tumors with Synthesized Literature Guidance
Adappa, Nithin D. , London, Nyall R. , Smith, Timothy L. , Su, Shirley Y. , Wang, Marilene B. , Adappa, Nithin D. , Kuan, Edward C , Holtzman, Adam L. , Wang, Marilene B , Su, Shirley Y , Wang, Eric W , Adappa, Nithin D. , Beswick, Daniel M.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | May 23, 2024 | Volume: 86 | Issue: 03 | Pages: 373-376

10.1055/s-0044-1787155 | PMID 40351885 Get It

Ten Years of Pathology on Twitter (X): Landscape and Evolution of Pathology on Twitter From 2012 to 2023
Tian, Roland, Wang, Eric , Sivasubramaniam, Priyadharshini , Baskota, Swikrity Upadhyay , Sharma, Anurag , Cecchini, Matthew J.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | April 10, 2024 | Volume: 149 | Issue: 1 | Pages: 75-82

10.5858/arpa.2023-0447-oa | PMID 38599590 Get It

Context.— Social media is a powerful tool in pathology education and professional networking that connects pathologists and pathology trainees from around the world. Twitter (X) appears to be the most popular social media platform pathologists use to share pathology-related content and connect with other pathologists. Although there has been some published research on pathology-related activity on Twitter during short time frames, to date there has not been published research examining pathology-related Twitter activity in totality from its earliest days of activity to recently. Objective.— To comprehensively evaluate the use of pathology on Twitter (X) during the last 10 years. Design.— Pathology-related tweets were systematically scraped from Twitter from January 2012 to January 2023 using pathology hashtags as a surrogate measure for all pathology content on Twitter. COVID-related tweets were approximated by tweets containing the term “COVID.” Results.— There were 591 812 unique pathology-related tweets identified during the time period, with #pathology being the most common hashtag used and #PathTwitter becoming more popular since 2020. There has been positive annual growth of pathology Twitter, with peaks in use during major pathology conferences. During the initial phases of the COVID-19 pandemic, a sustained increase in pathology tweets was observed. Conclusions.— Pathology Twitter has grown during the last 10 years and has become increasingly popular for pathology education and networking. With the changing landscape of social media platforms, this study provides an understanding of how pathology medical education and professional networking uses of social media happen and evolve over time.
Recurrence morbidity of olfactory neuroblastoma
Melder, Katie , Mace, Jess C. , Champagne, Pierre‐Olivier , Chan, Erik, Ciporen, Jeremy , Chaskes, Mark B., Fernandez‐Miranda, Juan C. , Fung, Nicholas K., Gardner, Paul A. , Hwang, Peter H. , Ji, Keven Seung Yong , Kalyvas, Aristotelis , Kong, Keonho A., Patel, Chirag , Patel, Zara M. , Celda, María Peris, Thorp, Brian D. , Zenonos, Georgios A. , Zwagerman, Nathan T. , Sanusi, Olabisi , Choby, Garret , Hwang, Peter H , Patel, Zara , Snyderman, Carl H , Wang, Eric W , Choby, Garret , Almeida, João Paulo , Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van , Geltzeiler, Mathew

Mayo Clinic

International Forum of Allergy & Rhinology | April 3, 2024 | Volume: 14 | Issue: 9 | Pages: 1435-1445

10.1002/alr.23351 | PMID 38567900 Get It

AbstractBackgroundWith modern treatment paradigms, olfactory neuroblastoma (ONB) has favorable overall survival (OS); however, the incidence of recurrence remains high. The primary aims of this study were to delineate the prognosis of recurrence of ONB and explore how recurrence subsites are associated with OS, disease‐specific survival (DSS), and further recurrence.MethodsA retrospective chart review of ONB cases from nine academic centers between 2005 and 2021 was completed. Tumor characteristics, recurrence subsites, timelines to recurrence, additional recurrences, and survival estimates were determined using descriptive and time‐to‐event analyses.ResultsA final cohort of 233 patients was identified, with 70 (30.0%) patients recurring within 50.4 (standard deviation ±40.9) months of diagnosis on average, consisting of local (50%), neck (36%), intracranial (9%), and distant (6%) recurrence. Compared with subjects without recurrence, patients with recurrence had significantly different primary American Joint Committee on Cancer T stage (p < 0.001), overall stage (p < 0.001), and modified Kadish scores (p < 0.001). Histopathology identified that dural involvement and positive margins were significantly greater in recurrent cases. First recurrence was significantly associated with worse 5‐year DSS (hazard ratio = 5.62; p = 0.003), and subjects with neck or local recurrence had a significantly better DSS compared to intracranial or distant recurrence.ConclusionsRecurrent cases of ONB have significantly different stages and preoperative imaging factors. Patients with local or neck recurrence, however, have better DSS than those with intracranial or distant recurrence, independent of initial tumor stage or Hyams grade. Identifying specific factors that confer an increased risk of recurrence and DSS is important for patient counseling in addition to surveillance planning.
Methodological and statistical characteristics of meta-analyses on spinal cord stimulation for chronic pain: a systematic review
Kleppel, Donald J , Copeland, Royce , Hussain, Nasir , Wang, Eric J. , D’Souza, Ryan S. , Wang, Eric , D'Souza, Ryan S , Karri, Jay

Mayo Clinic

Regional Anesthesia & Pain Medicine | February 22, 2024 | Volume: 50 | Issue: 4 | Pages: 358-366

10.1136/rapm-2023-105249 | PMID 38388015 Get It

Background A growing number of meta-analyses (MA) have investigated the use of spinal cord stimulation (SCS) as a treatment modality for chronic pain. The quality of these MAs has not been assessed by validated appraisal tools. Objective To examine the methodological characteristics and quality of MAs related to the use of SCS for chronic pain syndromes. Evidence review An online literature search was conducted in Ovid MEDLINE(R), Ovid EMBASE, Ovid Cochrane Database of Systematic Reviews, and Scopus databases (January 1, 2000 through June 30, 2023) to identify MAs that investigated changes in pain intensity, opioid consumption, and/or physical function after SCS for the treatment of chronic pain. MA quality was assessed using A Measurement Tool to Assess Systematic Reviews (AMSTAR-2) critical appraisal tool. Findings Twenty-five MAs were appraised in the final analysis. Three were considered “high” quality, three “low” quality, and 19 “critically low” quality, per the AMSTAR-2 criteria. There was no association between the publication year and AMSTAR-2 overall quality (β 0.043; 95% CI −0.008 to 0.095; p=0.097). There was an association between the impact factor and AMSTAR-2 overall quality (β 0.108; 95% CI 0.044 to 0.172; p=0.002), such that studies published in journals with higher impact factors were associated with higher overall quality. There was no association between the effect size and AMSTAR-2 overall quality (β −0.168; 95% CI −0.518 to 0.183; p=0.320). According to our power analysis, three studies were adequately powered (>80%) to reject the null hypothesis, while the remaining studies were underpowered (<80%). Conclusions The study demonstrates a critically low AMSTAR-2 quality for most MAs published on the use of SCS for treating chronic pain. Future MAs should improve study quality by implementing the AMSTAR-2 checklist items. PROSPERO registration number CRD42023431155.